Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Myelodysplasia risk high in RCC patients

Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

Key clinical point: Patients with a history of renal cell carcinoma have a substantially increased risk of developing myelodysplastic syndromes as compared to the general population. Given the strong association, an unexplained cytopenia in patients with a history of nephrectomy for localized RCC would warrant a strong consideration for a bone marrow biopsy to detect myelodysplasia.

Major finding: The prevalence of myelodysplastic syndromes in patients over 65 years old with a history of nephrectomy for RCC was 8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. 47/100,000), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs 128.4/100,000. Both differences were statistically significant (P less than 0.001).

Study details: Mayo Clinic’s ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both malignancies. Prevalence of myelodysplastic syndromes was noted in patients aged 65 years and older with a history of nephrectomy for RCC and was compared to the prevalence of myelodysplastic syndromes in the Dusseldorf MDS registry and the general patient population at Mayo Clinic.

Disclosures: The authors had no relevant financial disclosures.

Source: Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

Citation:

Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

This Week's Must Reads

CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold

If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder

Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.

Proposed fee schedule for 2019 could cut EHR hours, https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-14985.pdf

Must Reads in Renal Cell Carcinoma

EBUS-TBNA guides need for further treatment in RCC, Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.

Clear cell papillary RCC distinguished by unique staining pattern, Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007

Myelodysplasia risk high in RCC patients, Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

Pembrolizumab in advanced clear cell RCC, McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.

Do docetaxel nanoparticles boost response in mCRPC?, Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.